Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sumanirole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.82 |
| ▸ | HTR1A | P08908 | 17/20 | 0.82 |
| ▸ | DRD3 | P35462 | 7/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sumanirole SCHEMBL1229224 | 1.00 | HTR1A (0.82) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL29518262 | 0.91 | HTR1A (1.00) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL30503038 | 0.91 | HTR1A (1.00) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL6269816 | 0.91 | HTR1A (1.00) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL154412 | 0.91 | HTR1A (1.00) | HTR1ADRD2DRD3 | |
| Sumanirole SCHEMBL5906552 | 0.89 | HTR1A (0.97) | HTR1ADRD2DRD3 | |
| Maleic Acid SCHEMBL5906535 | 0.88 | HTR1A (0.62) | HTR1ADRD2DRD3 | |
| Fumaric Acid SCHEMBL5906537 | 0.88 | HTR1A (0.62) | HTR1ADRD2DRD3 | |
| SCHEMBL5424144 | 0.82 | HTR1A (0.70) | HTR1ADRD2DRD3 | |
| Pamoic Acid SCHEMBL5764309 | 0.77 | HTR1A (0.61) | HTR1ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716854-B2 | 3-(3-(METHYLSULFONYL)PHENYL)-1-PROPYLPIPERIDINE; SUBSTITUTED PHENYLAZACYCLOALKANES; DOPAMINERGIC | PFIZER, INC. | 2004-04-06 | — | — | US | disclosed |
| US-20030212065-A1 | TREATMENTS FOR RESTLESS LEGS SYNDROME | MCBRINN SYLVIA (US) | 2003-11-13 | — | — | US | disclosed |
| US-6602868-B2 | Administering a heterocyclic amine or a phenylazacycloalkane | PHARMACIA & UPJOHN COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20020107257-A1 | Treatments for restless legs syndrome | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | disclosed |
| US-20010053386-A1 | (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one maleate | PHARMACIA & UPJOHN COMPANY | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107257-A1 | Treatments for restless legs syndrome | HCRTR2, PNMT, HCRTR1 | DRD2 189/4885HTR1A 34/4885DRD3 329/4885 |
| US-20030212065-A1 | TREATMENTS FOR RESTLESS LEGS SYNDROME | HCRTR2, PNMT, HCRTR1 | DRD2 189/4885HTR1A 34/4885DRD3 329/4885 |
| US-20010053386-A1 | (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one maleate | MT-ND4, SNCA, PARK7 | DRD2 285/4885HTR1A 89/4885DRD3 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.